Scientists mapped what happens if a crucial system of ocean currents collapses. The weather impact would be extreme
Climate changeFacebookTweetLink
Follow
The collapse of a crucial network of Atlantic Ocean currents could push parts of the world into a deep freeze, with winter temperatures plunging to around minus 55 degrees Fahrenheit in some cities, bringing 'profound climate and societal impacts,' according to a new study.
There is increasing concern about the future of the Atlantic Meridional Overturning Circulation — known as the AMOC — a system of currents that works like a giant conveyor belt, pulling warm water from the Southern Hemisphere and tropics to the Northern Hemisphere, where it cools, sinks and flows back south.
Multiple studies suggest the AMOC is weakening with some projecting it could even collapse this century as global warming disrupts the balance of heat and salinity that keeps it moving. This would usher in huge global weather and climate shifts — including plunging temperatures in Europe, which relies on the AMOC for its mild climate.
What's less clear, however, is how these impacts will unfold in a world heated up by humans burning fossil fuels.
'What if the AMOC collapses and we have climate change? Does the cooling win or does the warming win?' asked René van Westen, a marine and atmospheric researcher at Utrecht University in the Netherlands and co-author of the paper published Wednesday in the Geophysical Research Letters journal.
This new study is the first to use a modern, complex climate model to answer the question, he told CNN.
The researchers looked at a scenario where the AMOC weakens by 80% and the Earth is around 2 degrees Celsius warmer than the period before humans began burning large amounts of fossil fuels. The planet is currently at 1.2 degrees of warming.
They focused on what would happen as the climate stabilized post-collapse, multiple decades into the future.
Even in this hotter world, they found 'substantial cooling' over Europe with sharp drops in average winter temperatures and more intense cold extremes — a very different picture than the United States, where the study found temperatures would continue to increase even with an AMOC collapse.
Sea ice would spread southward as far as Scandinavia, parts of the United Kingdom and the Netherlands, the research found. This would have a huge impact on cold extremes as the white surface of the ice reflects the sun's energy back into space, amplifying cooling.
The scientists have created an interactive map to visualize the impacts of an AMOC collapse across the globe.
London, for example, could see winter cold extremes of minus 2.2 Fahrenheit , while Oslo could see temperatures as low as minus 55 Fahrenheit and endure maximum temperatures below 32 Fahrenheit for 46% of the year.
Parts of Europe will also become stormier, the study found. The increased temperature difference between northern and southern Europe will strengthen the jet stream and increase storm intensity over northwestern Europe.
It 'completely shifts the narrative, right?' van Westen said. 'Because now policy is planning for a warmer future, but maybe instead, we need to also prepare for a colder future.'
While cooling on an ever-hotter planet may sound like good news, van Westen warns it's anything but.
Society in many parts of the Northern Hemisphere 'is not built for these kind of cold extremes,' he said. Crops would die, threatening food security, and infrastructure could buckle.
What's more, the impacts of an AMOC collapse would mostly be felt in Europe's winter; it would still endure increasingly deadly heat waves in the summer as the climate crisis intensifies.
The Southern Hemisphere, meanwhile, is projected to experience increased warming.
The scientists also looked at the impacts of an AMOC collapse in an even hotter world. If global temperatures reach around 4 degrees Celsius above pre-industrial levels, the heat outweighs the cooling impact of an AMOC collapse in Europe, van Westen said. 'The warming signal actually wins.'
But, he added, an AMOC collapse won't only affect temperatures. Other impacts include increased sea level rise, which will particularly affect the US, where a weaker AMOC is already driving significantly increased flooding on the northeastern coast, according to recent research.
Stefan Rahmstorf, a physical oceanographer at Potsdam University in Germany who was not involved in the latest research, said the study confirms 'an AMOC collapse would have massive impacts on European climate.'
The research uses only one climate model; others will rely on different models and will likely come up with a variety of scenarios, he told CNN. What ultimately happens will depend on the how the two opposing trends play out: AMOC-induced cooling and climate change-induced heating. A 'large uncertainty' remains, he said.
The study is 'by no means the last word' especially as huge questions remain over whether the AMOC could be on course to collapse, said Richard Allen, a climate science professor at the University of Reading, also not involved in the research. 'But even the mere possibility of this dire storyline unfolding over coming centuries underscores the need to forensically monitor what is happening in our oceans,' he said.
What is crystal clear is that an AMOC collapse would be very bad for society, van Westen said. 'We want to avoid it at all costs.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
32 minutes ago
- Associated Press
Sustainable technology awarded at 2025 Young Inventors Prize ceremony
MUNICH and REYKJAVIK, Iceland, June 23, 2025 /PRNewswire/ -- During a ceremony held today in Iceland, the European Patent Office (EPO) has awarded three special prizes as part of the 2025 Young Inventors Prize. These recognise outstanding achievements by inventors aged 30 and under whose work supports the United Nations Sustainable Development Goals (SDGs). A fourth distinction, the People's Choice winner, was awarded to Spanish inventors Granado, Sosa and Chimeno, after having ranked first in the public vote. The ten winners of this year's Young Inventors Prize — known as the Tomorrow Shapers — were selected by an independent jury from over 450 candidates worldwide, each receiving EUR 5 000. From this group, the jury awarded special recognition to Marie Perrin (France/US), Sandra Namboozo and Samuel Muyita (Uganda), and Neeka and Leila Mashouf (US) naming them World Builders, Community Healers, and Nature Guardians, respectively, with each receiving an additional EUR 15 000. The team of Spanish inventors Granado, Sosa and Chimeno was also chosen by public vote as the People's Choice winner, earning a further EUR 5 000. World Builders prize Marie Perrin (28), a French-American chemist based in Switzerland, was awarded the World Builders Prize for her invention– a cleaner method to recycle rare earth elements (REEs) from discarded fluorescent lamps. Rare earths are essential to electronics and green tech, but difficult and environmentally damaging to extract. Perrin's method, commercialised through her company REEcover, avoids harmful solvents and complex purification, making it easier to reuse resources instead of relying on new mining. The process achieves selective recovery of europium while preserving the ability to reuse chemicals, significantly reducing toxic waste compared to conventional methods. 'It has been a true privilege to stand alongside such inspiring young innovators from across the globe, and I hope it encourages more young women to see themselves as inventors and changemakers,' said Perrin. The World Builders prize honours innovators advancing sustainable access to essential resources, such as water, energy and infrastructure. Their work drives circular economy solutions that promote prosperity while reducing environmental impact. Community Healers prize Ugandan entrepreneurs Sandra Namboozo (26) and Samuel Muyita (28) received the Community Healers Prize for having developed a biodegradable sachet that triples the shelf life of fruit without refrigeration. The sachets release plant-based compounds that slow down ripening and help to reduce food waste. The duo founded Karpolax to commercialise their work and support smallholder farmers. In pilot tests, Karpolax-treated mangoes remained fresh for 33 days, compared to just 11 days for untreated fruits. 'Winning a special prize is a powerful validation,' said Namboozo and Muyita. 'It shines a global spotlight on a simple truth: innovation rooted in empathy can change the world.' The Community Healers prize recognises changemakers focused on social equity through solutions in food security, healthcare, education and fair working conditions. Nature Guardians prize Twin sisters Neeka and Leila Mashouf (28), from the United States, were awarded the Nature Guardians prize for a carbon capture process that mimics photosynthesis. Through their company Rubi Laboratories, they developed an enzymatic method that converts CO₂ emissions into biodegradable cellulose for textiles and other products. The company's closed-loop system uses carbon from manufacturing waste streams to produce regenerated fabric without fossil-based fibres or dyes. 'It took countless trials, errors and optimisations to make it all work,' said Neeka. 'From producing enzymes that had never been made before to testing them in conditions no one had ever explored.' The Nature Guardians prize celebrates innovators dedicated to protecting ecosystems and biodiversity, addressing climate change, ocean health and wildlife conservation. People's Choice winner Spanish entrepreneurs Pilar Granado (29), Pablo Sosa Domínguez (29) and Luis Chimeno (28) are the People's Choice winners. Their innovation of smart labels that indicate food spoilage based on bacterial growth was selected by public vote for its potential to help reduce food waste and increase food safety, while promoting sustainability across the supply chain. 'We are very excited and grateful for the recognition! It is a motivational boost for us, as this award shows that we are on the right track and that our solution could really change the world, taking a positive step towards a more sustainable and safer supply chain for all', said the team. The People's Choice is chosen by the general public. Voting opened online on 6 May when all the Tomorrow Shapers were announced and closed just before the ceremony started. The Young Inventors Prize celebrates worldwide innovators 30 and under using technology to address global challenges posed by the United Nations Sustainable Development Goals (SDGs). The winners of the 2025 edition were announced today during a ceremony livestreamed from Iceland. Find more information about the inventions, their impact and the inventors' stories here. About the Young Inventors Prize Aimed at individuals 30 and under, the Young Inventors Prize showcases the transformative power of youth-driven solutions and recognises the remarkable young people paving the way to a more sustainable future. Established in 2022, trophies were first handed out during the European Inventor Award ceremony. As of 2025, the Prize has moved up a gear with its own dedicated event, held separately from the Award. Among the 10 Tomorrow Shapers selected for each edition, three receive special prizes: World Builders, Community Healers, and Nature Guardians. In addition, a People's Choice winner is selected through an online public vote. Each Tomorrow Shaper receives EUR 5 000, while the three special prize winners are awarded an additional EUR 15 000. The People's Choice winner also receives an extra EUR 5 000. Read more on the Young Inventors Prize eligibility and selection criteria. About the EPO With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching. *Important note B-roll and picture materials of the inventors/invention here Additional videos and photos from the ceremony will be available shortly Full ceremony video available upon request View original content: SOURCE European Patent Office (EPO)
Yahoo
an hour ago
- Yahoo
Why nightmares could make you age faster and die sooner
Frequent nightmares are linked to premature ageing and increase the risk of an early death, according to a new study. Adults who report weekly nightmares are more than three times likely to die before the age of 70 compared to those who rarely or never experience them, researchers found. The study found nightmares to be a 'stronger predictor of premature death' than smoking, obesity, poor diet, and low physical activity. The scientists warned the findings should be treated as a 'public health concern', but said people can reduce nightmares by managing stress. The team, led by Dr Abidemi Otaiku of the UK Dementia Research Institute, and Imperial College London, analysed data from 2,429 children aged eight to 10 and 183,012 adults aged 26 to 86 over a period of 19 years. The research, presented at the European Academy of Neurology (EAN) Congress this month, found that nightmares disrupt both sleep quality and duration, which impairs the body's overnight cellular restoration and repair ability. The combined impacts of chronic stress and disrupted sleep are likely to contribute to the accelerated ageing of our cells and bodies. Dr Otaiku said, 'Our sleeping brains cannot distinguish dreams from reality. That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake.' He said: 'Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process.' He added: 'Given how common and modifiable nightmares are, they should be taken far more seriously as a public health concern.' Researchers found that children and adults who had frequent nightmares also exhibited faster ageing. This accounted for approximately 40 per cent of those who had a higher risk of early death. Dr Otaiku said this was the first study to show nightmares can predict faster biological ageing and earlier mortality, even after accounting for other health issues. Even monthly nightmares were linked to faster ageing and increased mortality compared to those who had no nightmares. and the links were consistent across all ages, sexes, ethnicities, and mental health statuses. 'The good news is that nightmares can be prevented and treated,' said Dr Otaiku. Simple measures, such as maintaining good sleep hygiene, managing stress, seeking treatment for anxiety or depression and not watching scary films can be effective in reducing nightmares, he said.
Yahoo
4 hours ago
- Yahoo
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2 Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1 TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1 The final data was presented at the Congress of the European Academy of Neurology (EAN 2025) congress in Helsinki confirming that primary and secondary endpoints had been met.1 Investigators concluded that the findings underscore the sustained effectiveness and the robust injection adherence rates to long-term fremanezumab treatment in migraine prevention.1 'Over the last two years, we have observed the benefit of fremanezumab for sustained migraine prevention and its positive impact on patient outcomes,' says Messoud Ashina, Professor and Director of the Human Migraine Research Unit, the Danish Headache Center and Department of Neurology. 'The PEARL study has provided valuable insight, not only into the pivotal role that fremanezumab can play in migraine prevention, but also in the importance of real-world studies in helping build our knowledge and shape clinical practice.' PEARL, a 24-month real-world observational study assessed the impact of fremanezumab for migraine prevention in 1,140 patients, predominantly female (87.25%) with 33.1% living with episodic migraine (EM), and 66.9% with chronic migraine (CM). The final study showed that over 66% of patients with EM and 51.6% with CM who had achieved the primary endpoint of a ≥50% reduction in Monthly Migraine Days (MMD) during the first 6 months of treatment benefitted from sustained migraine prevention for over 24 months. Injection adherence rates remained high throughout (~90%) the study, with over 75% (854/1129) of participants completing the study duration.1 The investigators also noted the favourable long-term safety and tolerability of fremanezumab that was consistent with its known safety profile from previous PEARL interim analyses and randomised controlled trials, supporting its continued clinical use for migraine prevention.2 'The final analysis of the PEARL real-world study reaffirms the long-term effectiveness and safety profile of fremanezumab in the preventive treatment of chronic and episodic migraine,' said Pinar Kokturk, M.D., Vice President and Head of Medical Affairs Europe at Teva. 'These data provide valuable real-world evidence supporting fremanezumab's sustained clinical benefit, particularly in a population burdened by high disease impact and a need for preventive therapy. With migraine being the second leading cause of disability worldwide,3 the recognition of CGRP-pathway therapies by health authorities is critical for improving patient outcomes.' Editors' Notes PEARL (Pan-European Real-World study), a two-year prospective, observational Phase IV study is investigating the effectiveness of AJOVY® (fremanezumab) in 1140 patients with chronic or episodic migraine. Fremanezumab is a humanised monoclonal antibody (mAb) that selectively targets the calcitonin gene-related peptide (CGRP) pathway. Of the 1140 participants enrolled, 1129 were included in the effectiveness analysis (EM, 33.1%; CM, 66.9%; 87.2% female). Eligible participants were adults with EM or CM receiving fremanezumab for migraine prevention, who maintained a daily headache diary prior to and throughout the study period. The primary endpoint was the proportion of participants with >=50% reduction in monthly migraine days (MMD) during the 6-month period after fremanezumab initiation. Secondary endpoints across Months 1–24 included mean change from baseline in MMD, and treatment adherence (participants who took their prescribed dose within ±5 days of the scheduled monthly/quarterly dosing regimen, per injection) and persistence. About AJOVY® (fremanezumab-vfrm) injection AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen. Two dosing options are available: 225 mg once monthly administered as one subcutaneous injection (monthly dosing), or 675 mg every three months (quarterly dosing), which is administered as three subcutaneous injections. AJOVY can be administered either by a health care professional or at home by a patient or caregiver. No starting dose is required to begin treatment. Information for Europe about AJOVY can be found here. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit Cautionary Note Regarding Forward-Looking Statements This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of chronic or episodic migraine; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations Inquires:TevaIR@ References 1. Ashina M. et al, Real-World Effectiveness of Fremanezumab in Migraine Prevention: Final Outcomes of the Pan-European PEARL Study (EPR-039), poster presented at the European Academy of Neurology (EAN) Congress; 21 – 24 June, 2025; Helsinki, Finland.2. Ashina M et al, Real-World Safety and Tolerability of Fremanezumab in Migraine Prevention: Final Outcomes of the PEARL Study (EPO-063), poster presented at the European Academy of Neurology (EAN) Congress; 21 – 24 June, 2025; Helsinki, Finland.3. Steiner, T.J., Stovner, L.J., Jensen, R. et al. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21, 137 (2020).Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
